Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02918994 · ClinicalTrials.gov registry record · NA

LearningRx Cognitive Training for Brain Injury

A NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI), sponsored by Gibson Institute of Cognitive Research.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02918994: Active NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI), sponsored by Gibson Institute of Cognitive Research.

NCT02918994 is a NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI) that is active but no longer recruiting, run by Gibson Institute of Cognitive Research. The registered enrollment target is 30 participants, below the 76-participant average among 10 other Acquired Brain Injury trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02918994, a NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI), is active but no longer recruiting, sponsored by Gibson Institute of Cognitive Research.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain Injury (TBI) /Acquired Brain Injury (ABI).

Primary Outcome

Confirmed by change on 29-item Workplace Self-Efficacy Survey

Interventions

  • BEHAVIORAL LearningRx cognitive training

Study Locations (1)

Colorado

  • Gibson Institute of Cognitive Research - Colorado Springs

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-09
Est. Completion 2027-12
Phase NA

What the registry record for NCT02918994 still lists

NCT02918994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 76-participant average among 10 other Acquired Brain Injury trials with a reported enrollment target (61% lower).

The record links to 3 conditions, with Acquired Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which LearningRx cognitive training is the first listed.

NCT02918994 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT02918994 about?

NCT02918994 is a clinical study titled "LearningRx Cognitive Training for Brain Injury". The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain Injury (TBI) /Acquired Brain Injury (ABI).

What is the current status of trial NCT02918994?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2016-09. Estimated completion is 2027-12.

What conditions does trial NCT02918994 study?

This clinical trial studies the following conditions: Acquired Brain Injury, Traumatic Brain Injury (TBI), Post COVID-19 Cognitive Impairment.

What interventions are being tested in trial NCT02918994?

The interventions under investigation include: LearningRx cognitive training (BEHAVIORAL).

Who is sponsoring clinical trial NCT02918994?

This trial is sponsored by Gibson Institute of Cognitive Research, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02918994 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acquired Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02918994's enrollment target sits among peer trials

30 6th of 10 higher than 4 of 10 other Acquired Brain Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acquired Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02918994, the US trial registry maintained by the National Library of Medicine. NCT02918994 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.